Phaseline

Companies › CeleCor Therapeutics

CeleCor Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Cardiovascular.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Zalunfiban
Integrin alpha-IIb/beta-3 inhibitor
ITGB3, ITGA2BPhase 3ST-elevation Myocardial Infarction (STEMI)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04825743ZalunfibanPhase 3ST-elevation Myocardial Infarction (STEMI)CardiovascularMay 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

ITGB3 (1) ITGA2B (1)

Companies with the same targets

–

Companies built like this

MedTrace Pharma SPH Qingdao Growful Pharmacetical Hanlim Pharm. Trust Bio-sonics Liquidia Technologies

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.